227 related articles for article (PubMed ID: 27054934)
1. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.
Lee AW; Ness RB; Roman LD; Terry KL; Schildkraut JM; Chang-Claude J; Doherty JA; Menon U; Cramer DW; Gayther SA; Risch H; Gentry-Maharaj A; Goodman MT; Modugno F; Eilber U; Moysich KB; Berchuck A; Rossing MA; Jensen A; Wicklund KG; Cushing-Haugen KL; Hogdall E; Rudolph A; Thompson PJ; Wilkens LR; Kjaer SK; Carney ME; Stram DO; Ramus SJ; Wu AH; Pike MC; Pearce CL;
Obstet Gynecol; 2016 May; 127(5):828-836. PubMed ID: 27054934
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
[TBL] [Abstract][Full Text] [Related]
3. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.
Lee AW; Bomkamp A; Bandera EV; Jensen A; Ramus SJ; Goodman MT; Rossing MA; Modugno F; Moysich KB; Chang-Claude J; Rudolph A; Gentry-Maharaj A; Terry KL; Gayther SA; Cramer DW; Doherty JA; Schildkraut JM; Kjaer SK; Ness RB; Menon U; Berchuck A; Mukherjee B; Roman L; Pharoah PD; Chenevix-Trench G; Olson S; Hogdall E; Wu AH; Pike MC; Stram DO; Pearce CL;
Int J Cancer; 2016 Dec; 139(12):2646-2654. PubMed ID: 27420401
[TBL] [Abstract][Full Text] [Related]
4. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
Lee AW; Wu AH; Wiensch A; Mukherjee B; Terry KL; Harris HR; Carney ME; Jensen A; Cramer DW; Berchuck A; Doherty JA; Modugno F; Goodman MT; Alimujiang A; Rossing MA; Cushing-Haugen KL; Bandera EV; Thompson PJ; Kjaer SK; Hogdall E; Webb PM; Huntsman DG; Moysich KB; Lurie G; Ness RB; Stram DO; Roman L; Pike MC; Pearce CL;
Epidemiology; 2020 May; 31(3):402-408. PubMed ID: 32028322
[TBL] [Abstract][Full Text] [Related]
5. Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
Grandi G; Perrone AM; Chiossi G; Friso S; Toss A; Sammarini M; Facchinetti F; Botticelli L; Palma F; De Iaco P
Gynecol Oncol; 2019 Jul; 154(1):163-168. PubMed ID: 31104904
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
Petrick JL; Joslin CE; Johnson CE; Camacho TF; Peres LC; Bandera EV; Barnard ME; Beeghly A; Bethea TN; Dempsey LF; Guertin K; Harris HR; Moorman PG; Myers ER; Ochs-Balcom HM; Rosenow W; Setiawan VW; Wu AH; Schildkraut JM; Rosenberg L
Br J Cancer; 2023 Dec; 129(12):1956-1967. PubMed ID: 37865688
[TBL] [Abstract][Full Text] [Related]
8. Pelvic inflammatory disease and risk of epithelial ovarian cancer: a national population-based case-control study in Sweden.
Jonsson S; Jonsson H; Lundin E; Häggström C; Idahl A
Am J Obstet Gynecol; 2024 Jan; 230(1):75.e1-75.e15. PubMed ID: 37778677
[TBL] [Abstract][Full Text] [Related]
9. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
Wentzensen N; Poole EM; Trabert B; White E; Arslan AA; Patel AV; Setiawan VW; Visvanathan K; Weiderpass E; Adami HO; Black A; Bernstein L; Brinton LA; Buring J; Butler LM; Chamosa S; Clendenen TV; Dossus L; Fortner R; Gapstur SM; Gaudet MM; Gram IT; Hartge P; Hoffman-Bolton J; Idahl A; Jones M; Kaaks R; Kirsh V; Koh WP; Lacey JV; Lee IM; Lundin E; Merritt MA; Onland-Moret NC; Peters U; Poynter JN; Rinaldi S; Robien K; Rohan T; Sandler DP; Schairer C; Schouten LJ; Sjöholm LK; Sieri S; Swerdlow A; Tjonneland A; Travis R; Trichopoulou A; van den Brandt PA; Wilkens L; Wolk A; Yang HP; Zeleniuch-Jacquotte A; Tworoger SS
J Clin Oncol; 2016 Aug; 34(24):2888-98. PubMed ID: 27325851
[TBL] [Abstract][Full Text] [Related]
10. The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.
Shafrir AL; Rice MS; Gupta M; Terry KL; Rosner BA; Tamimi RM; Hecht JL; Tworoger SS
Gynecol Oncol; 2016 Dec; 143(3):628-635. PubMed ID: 27720231
[TBL] [Abstract][Full Text] [Related]
11. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.
Rodriguez C; Patel AV; Calle EE; Jacob EJ; Thun MJ
JAMA; 2001 Mar; 285(11):1460-5. PubMed ID: 11255422
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and risk of ovarian cancer.
Leitzmann MF; Koebnick C; Danforth KN; Brinton LA; Moore SC; Hollenbeck AR; Schatzkin A; Lacey JV
Cancer; 2009 Feb; 115(4):812-22. PubMed ID: 19127552
[TBL] [Abstract][Full Text] [Related]
13. Menopausal hormone replacement therapy and risk of ovarian cancer.
Lacey JV; Mink PJ; Lubin JH; Sherman ME; Troisi R; Hartge P; Schatzkin A; Schairer C
JAMA; 2002 Jul; 288(3):334-41. PubMed ID: 12117398
[TBL] [Abstract][Full Text] [Related]
14. The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States.
Cramer DW; Vitonis AF; Terry KL; Welch WR; Titus LJ
Epidemiology; 2016 May; 27(3):334-46. PubMed ID: 26689397
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for different histological types of ovarian cancer.
Parazzini F; Chiaffarino F; Negri E; Surace M; Benzi G; Franceschi S; Fedele L; La Vecchia C
Int J Gynecol Cancer; 2004; 14(3):431-6. PubMed ID: 15228415
[TBL] [Abstract][Full Text] [Related]
16. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
19. Hormone therapy and different ovarian cancers: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
[TBL] [Abstract][Full Text] [Related]
20. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.
Yarmolinsky J; Relton CL; Lophatananon A; Muir K; Menon U; Gentry-Maharaj A; Walther A; Zheng J; Fasching P; Zheng W; Yin Ling W; Park SK; Kim BG; Choi JY; Park B; Davey Smith G; Martin RM; Lewis SJ
PLoS Med; 2019 Aug; 16(8):e1002893. PubMed ID: 31390370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
